This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss an RCT, a pediatric RCT, and a pediatric RCT in childhood nephrotic syndrome! A trial that asks a question of burning importance to the management of childhood nephrotic syndrome. Join us as we tackle PREDNOS.
Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?
This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.
They always said not to correct hypernatremia faster than 0.5 mmol/L/hour but what do they know and who are they anyways? New data questions this ancient dogma.
In conjunction with NephMadness - Pain Region discussion, we discuss a recent JAMA Network Open study, reporting higher kidney risk in young men taking NSAIDs.
Can PIVOTAL pivot us to pump more iron? It is indeed a pivot from the lazy, halycon days of the ESA era, now to the evil ESA empire crumbling under the strong iron attack. Join us to discuss!
The fault, is not in our stars, or in our environment, but sometimes in ourselves. Nature, not just nurture, is more important than we knew. Join us, as we try to undertand the implications of this new research suggesting how many CKD cases have genetic underpinnings.
We complain about the quality of kidney research but is there any meat there? Join us this week as we look at Chatzimanouil’s recent examination of the nephrology literature.
First chat of 2019 - showcasing again the honest brokers of nephrology trials with another negative trial. Also note we will be having a NephJC Asia chat starting this week!
This week, we will discuss the use of lanreotide - a somoatostatin analogue, for the treatment of autosomal dominant polycystic kidney disease. An RCT, published in JAMA.
Join us to discuss this extension of the TUMORAPA trial - in a joint session with the #DermJC. Should kidney transplant recipients with squamous cell cancer be switched to sirolimus?
There is AKI. You are ready to discharge the patient. Should you restart their ACEI/ARB? Or they were never on an ACEI/ARB - but surely with a history of heart failure, they should be on one? How do you decide? Join us to discuss some exciting new data
This week we discuss the BICAR-ICU trial from France. In patients who are critically ill with metabolic acidosis, does giving bicarb help improve survival? More importantly, does it help with kidney outcomes? Join us to discuss
Proposition 8 is on the ballot. It pits the labor unions against the dialysis corporations. Simple right? Wrong. Check out the details and join us Oct 16.
This week, we discuss some amazing advances made in our understanding of the PKD protein - using a technology called CryoEM. Check out the video explainer and summary.
Join us as we discuss this study which meticulously collected data from Nicaragua to shed more light on the potential mechanism of mesoamerican nephropathy